- Case report
- Open Access
- Open Peer Review
Ocular pathology of uncommon hematologic malignancies: a case series
© Head et al; licensee BioMed Central Ltd. 2007
- Received: 06 June 2007
- Accepted: 28 November 2007
- Published: 28 November 2007
In general, ocular complications of hematologic malignancies such as leukemia are well documented. However, reports of ocular involvement in such diseases as lymphomatoid granulomatosis and chronic myelomonocytic leukemia are uncommon. Here we present cases of these two relatively rare hematologic malignancies demonstrating clinical and subclinical ocular involvement.
In the first case, a 54-year-old man with a previous diagnosis of lymphomatoid granulomatosis presented with a new-onset conjunctival lesion while his systemic disease was thought to be in remission. A biopsy was taken that revealed heavy infiltrates of B and T cells at the site of the lesion. Molecular analysis confirmed that these cells were positive for both Epstein-Barr viral DNA and immunoglobulin heavy chain gene rearrangement, consistent with a manifestation of his systemic disease. In the second case, a 51-year-old man with chronic myelomonocytic leukemia died after a waxing and waning clinical course. Post-mortem studies revealed the presence of atypical monocytes in the choroidal and subretinal spaces, consistent with his previous diagnosis.
While ocular involvement in hematologic malignancies is not uncommon, these two cases describe involvement of the eye by two relatively rare neoplasms. We herein emphasize novel findings in each case, including conjunctival involvement as the first sign of recurrent lymphomatoid granulomatosis and the combination of subretinal and choroidal myelomonocytic leukemic infiltration. With the evolution of new antineoplastic therapies that may prolong life, these cases exemplify the importance of eye care in patients diagnosed with hematologic malignancies.
- Hematologic Malignancy
- Optic Neuritis
- Retinal Hemorrhage
- Ocular Involvement
- Ocular Complication
Ocular complications of hematologic malignancies such as leukemia are well documented. It is estimated that 50% or more of all leukemias manifest some form of ocular involvement [1, 2]. Here we present the cases of two patients with relatively rare hematologic malignancies with notable pre- or post-mortem demonstrating clinical and pathological ocular involvement.
The first case demonstrates a LYG metastatic lesion to the conjunctiva. First described as a distinct clinical entity in 1972, LYG is a rare, angiocentric, angiodestructive disease that is infrequently associated with ocular manifestations . Though rare, the most commonly recognized pathology is consistent with the biopsy in this case, marked by the diffuse presence of B cells with an exuberant, attendant T-cell response. Current research suggests that LYG may be categorized as an EBV-related B-cell lymphoma . This conjunctival lesion, confirmed immunohistochemically and molecularly, was the first clinical sign of LYG recurrence detected in this patient.
It should be noted that although ocular manifestations in LYG are uncommon, case reports do exist that document involvement of structures including the optic nerve , retina, sclera, and eyelid. Conjunctival involvement has also previously been described . Reported clinical manifestations vary according to the ocular structure involved, but are generally diverse, ranging from ulcerative skin nodules  to sudden unilateral blindness to uveitis.
The second case involves a patient with chronic myelomonocytic leukemia (CMML), a disease formerly classified solely as a type of myelodysplastic syndrome (MDS) but reclassified in 1999 as a mixed MDS/myeloproliferative disorder .
Myelodysplastic syndrome (MDS) is a term that refers to a heterogeneous group of clonal bone marrow disorders associated with changes in marrow cellularity accompanied by dysmyelopoiesis and peripheral blood cytopenias . Many case reports exist in the literature demonstrating ocular involvement in patients with MDS. In a 2005 retrospective study, Kezuka et al. reported that nearly half of 41 patients with MDS studied went on to develop ocular complications including corneal ulcer, iridocyclitis, vitreous hemorrhage, retinal hemorrhage, nerve-fiber layer infarcts, and optic neuritis .
In contrast to MDS, ocular involvement in patients with CMML is rarely reported, perhaps owing in part to the fact that the severe, progressive illness faced by many of these patients limits the feasibility of ocular examinations. While the patient described in the second case had no documented visual symptoms, pathology demonstrates infiltration of atypical cells within the vasculature of the choroid bilaterally as well as a subretinal hemorrhage with leukemic infiltration in the left eye. To our knowledge, this combination of findings in a patient with CMML has not been previously reported.
We herein describe several microscopic ocular pathologic findings associated with two relatively rare hematologic malignancies. These cases emphasize both the ability of these diseases to demonstrate ocular involvement as well as important clinical and subclinical findings that may be seen with each. Furthermore, we emphasize the importance of an awareness of newly recognized manifestations of disease in cases such as these. In particular, the advent of novel antineoplastic therapies, with their associated potential to prolong life, may lead to the recognition of previously unobserved clinical signs. Our pathologic findings support that a routine eye examination, when possible, should be encouraged for patients with hematologic malignancies.
JEH was a fellow in the 2006–07 Clinical Research Training Program, a public-private partnership supported jointly by the NIH and Pfizer, Inc. (via a grant to the Foundation for the NIH from Pfizer, Inc.).
Written informed consents were obtained from the patient (Case 1) and relatives (Case 2) for the publication of this study.
- Shaikh A, Parulekar M, James B: Acute suprachoroidal haemorrhage with acute angle closure glaucoma as a presenting sign of chronic myelomonocytic leukemia. Eye (London, England). 2002, 16 (5): 651-653.View ArticleGoogle Scholar
- Reddy SC, Jackson N, Menon BS: Ocular involvement in leukemia--a study of 288 cases. Ophthalmologica. 2003, 217 (6): 441-445. 10.1159/000073077.View ArticlePubMedGoogle Scholar
- Chan CC: Molecular pathology of primary intraocular lymphoma. Trans Am Ophthalmol Soc. 2003, 101: 275-292.PubMedPubMed CentralGoogle Scholar
- Liebow AA, Carrington CR, Friedman PJ: Lymphomatoid granulomatosis. Hum Pathol. 1972, 3 (4): 457-558. 10.1016/S0046-8177(72)80005-4.View ArticlePubMedGoogle Scholar
- McNiff JM, Cooper D, Howe G, Crotty PL, Tallini G, Crouch J, Eisen RN: Lymphomatoid granulomatosis of the skin and lung. An angiocentric T-cell-rich B-cell lymphoproliferative disorder. Arch Dermatol. 1996, 132 (12): 1464-1470. 10.1001/archderm.132.12.1464.View ArticlePubMedGoogle Scholar
- Forman S, Rosenbaum PS: Lymphomatoid granulomatosis presenting as an isolated unilateral optic neuropathy. A clinicopathologic report. J Neuroophthalmol. 1998, 18 (2): 150-152.View ArticlePubMedGoogle Scholar
- Chung YM, Yeh TS, Tsai YY, Chiang H, Liu JH: Conjunctival involvement of lymphomatoid granulomatosis. Ophthalmologica. 1988, 196 (3): 161-166.View ArticlePubMedGoogle Scholar
- Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002, 100 (7): 2292-2302. 10.1182/blood-2002-04-1199.View ArticlePubMedGoogle Scholar
- Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD: Myelodysplastic syndromes: the complexity of stem-cell diseases. Nature reviews. 2007, 7 (2): 118-129. 10.1038/nrc2047.PubMedGoogle Scholar
- Kezuka T, Usui N, Suzuki E, Wakasugi K, Usui M: Ocular complications in myelodysplastic syndromes as preleukemic disorders. Jpn J Ophthalmol. 2005, 49 (5): 377-383. 10.1007/s10384-005-0228-6.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.